We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
QIAGEN (QGEN) & Verogen Team Up to Employ NGS-Based Forensics
Read MoreHide Full Article
QIAGEN N.V. (QGEN - Free Report) recently announced commercialization collaboration with Verogen to provide tools and support for human identification (HID) workflows in laboratories. Notably, the financial terms of the deal were kept under wraps.
Verogen and QIAGEN will also work together to commercialize a menu of forensically validated workflows for next-generation sequencing (NGS) that combine Verogen’s library-prep products with QIAGEN’s QIAseq products, automation solutions and expertise.
The collaboration is likely to expand QIAGEN’s forensic position and NGS-based solutions offering.
More in the News
The deal will expand QIAGEN’s forensics leadership that already covers sample collection and preparation, genetic testing analysis and workflow automation by enabling QIAGEN to provide Verogen’s preeminent HID sequencing and analysis solutions that run on MiSeq FGx sequencers from Illumina.
The agreement grants QIAGEN the rights to distribute the Verogen portfolio worldwide, including kits based on the proprietary Verogen ForenSeq assay -- the Verogen MiSeq FGx Sequencing System and the Universal Analysis Software. Notably, QIAGEN will market Verogen products together with its portfolio of forensics instruments, kits and services globally.
Significance of the Collaboration
The partnership will bring together QIAGEN’s leading portfolio of Sample to Insight solutions with Verogen’s innovative NGS workflows. The collaboration will drive the adoption of NGS in HID as it will enable customers to gain better insights from their casework samples and eventually strengthen decision-making systems all over the world.
Image Source: Zacks Investment Research
The combination of Verogen’s industry-leading NGS-based product portfolio with QIAGEN’s gold-standard extraction, assay and automation solutions will accelerate adoption and use of NGS in forensics.
Industry Prospects
Per a report by Fortune Business Insights, the global next-generation sequencing market size was valued at $6.33 billion in 2018 and is projected to reach $31.41 billion by 2026, at a CAGR of 22.2%.
Rising prevalence of chronic diseases, increased research and diversified application of NGS in diagnostics are driving the market.
Recent Developments
In June 2021, QIAGEN launched QIAprep& CRISPR Kit and CRISPR Q-Primer Solutions that enable researchers to explore edited genetic material with unparalleled speed and efficiency. The new products are an addition to the array of QIAGEN products that could also be used for CRISPR research such as the QIAGEN EndoFree Plasmid Kits and Plasmid Plus Kits.
In April 2021, QIAGEN announced the upcoming launch of the EZ2 Connect product line -- a next-level automated sample-processing platform for automated sample processing in biomedical research, forensics and clinical diagnostics. The EZ2 Connect instruments utilize pre-filled cartridges and magnetic bead technology to process up to 24 samples simultaneously within 20 minutes, ensuring process safety and efficiency of nucleic acid extraction.
Price Performance
Shares of the company have gained 15.3% in a year’s time against the industry’s fall of 1%.
Zacks Rank and Key Picks
Currently, the company carries a Zacks Rank #3 (Hold).
Envista Holdings has an estimated long-term earnings growth rate of 26%.
BellRing Brands has an estimated long-term earnings growth rate of 22%.
IDEXX Laboratories has a projected long-term earnings growth rate of 20%.
Bitcoin, Like the Internet Itself, Could Change Everything
Blockchain and cryptocurrency has sparked one of the most exciting discussion topics of a generation. Some call it the “Internet of Money” and predict it could change the way money works forever. If true, it could do to banks what Netflix did to Blockbuster and Amazon did to Sears. Experts agree we’re still in the early stages of this technology, and as it grows, it will create several investing opportunities.
Zacks’ has just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.
Image: Bigstock
QIAGEN (QGEN) & Verogen Team Up to Employ NGS-Based Forensics
QIAGEN N.V. (QGEN - Free Report) recently announced commercialization collaboration with Verogen to provide tools and support for human identification (HID) workflows in laboratories. Notably, the financial terms of the deal were kept under wraps.
Verogen and QIAGEN will also work together to commercialize a menu of forensically validated workflows for next-generation sequencing (NGS) that combine Verogen’s library-prep products with QIAGEN’s QIAseq products, automation solutions and expertise.
The collaboration is likely to expand QIAGEN’s forensic position and NGS-based solutions offering.
More in the News
The deal will expand QIAGEN’s forensics leadership that already covers sample collection and preparation, genetic testing analysis and workflow automation by enabling QIAGEN to provide Verogen’s preeminent HID sequencing and analysis solutions that run on MiSeq FGx sequencers from Illumina.
The agreement grants QIAGEN the rights to distribute the Verogen portfolio worldwide, including kits based on the proprietary Verogen ForenSeq assay -- the Verogen MiSeq FGx Sequencing System and the Universal Analysis Software. Notably, QIAGEN will market Verogen products together with its portfolio of forensics instruments, kits and services globally.
Significance of the Collaboration
The partnership will bring together QIAGEN’s leading portfolio of Sample to Insight solutions with Verogen’s innovative NGS workflows. The collaboration will drive the adoption of NGS in HID as it will enable customers to gain better insights from their casework samples and eventually strengthen decision-making systems all over the world.
Image Source: Zacks Investment Research
The combination of Verogen’s industry-leading NGS-based product portfolio with QIAGEN’s gold-standard extraction, assay and automation solutions will accelerate adoption and use of NGS in forensics.
Industry Prospects
Per a report by Fortune Business Insights, the global next-generation sequencing market size was valued at $6.33 billion in 2018 and is projected to reach $31.41 billion by 2026, at a CAGR of 22.2%.
Rising prevalence of chronic diseases, increased research and diversified application of NGS in diagnostics are driving the market.
Recent Developments
In June 2021, QIAGEN launched QIAprep& CRISPR Kit and CRISPR Q-Primer Solutions that enable researchers to explore edited genetic material with unparalleled speed and efficiency. The new products are an addition to the array of QIAGEN products that could also be used for CRISPR research such as the QIAGEN EndoFree Plasmid Kits and Plasmid Plus Kits.
In April 2021, QIAGEN announced the upcoming launch of the EZ2 Connect product line -- a next-level automated sample-processing platform for automated sample processing in biomedical research, forensics and clinical diagnostics. The EZ2 Connect instruments utilize pre-filled cartridges and magnetic bead technology to process up to 24 samples simultaneously within 20 minutes, ensuring process safety and efficiency of nucleic acid extraction.
Price Performance
Shares of the company have gained 15.3% in a year’s time against the industry’s fall of 1%.
Zacks Rank and Key Picks
Currently, the company carries a Zacks Rank #3 (Hold).
A few better-ranked stocks from the broader medical space are Envista Holdings Corporation (NVST - Free Report) , BellRing Brands, Inc. (BRBR - Free Report) and IDEXX Laboratories, Inc. (IDXX - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of Zacks #1 Rank (Strong Buy) stocks here.
Envista Holdings has an estimated long-term earnings growth rate of 26%.
BellRing Brands has an estimated long-term earnings growth rate of 22%.
IDEXX Laboratories has a projected long-term earnings growth rate of 20%.
Bitcoin, Like the Internet Itself, Could Change Everything
Blockchain and cryptocurrency has sparked one of the most exciting discussion topics of a generation. Some call it the “Internet of Money” and predict it could change the way money works forever. If true, it could do to banks what Netflix did to Blockbuster and Amazon did to Sears. Experts agree we’re still in the early stages of this technology, and as it grows, it will create several investing opportunities.
Zacks’ has just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.
See 3 crypto-related stocks now >>